Danish diabetes and weight loss juggernaut Novo Nordisk is to part ways with its chief executive Lars Fruergaard Jørgensen as ...

Chinese pharmaceutical group Jiangsu Hengrui Pharmaceuticals (SHE: 600276) is set to raise up to HK$9.89 billion ($1.27 ...

Telomir Pharmaceuticals (Nasdaq: TLO), a US age-reversal science-based biotech, has identified Telomir-Ag2 as a novel drug ...

US biopharma Biohaven has been told by the US Food and Drug Administration (FDA) that the agency is extending the PDUFA date ...

Pathos AI, a US biotech specializing in artificial intelligence for cancer drug development, has raised $365 million in a ...

Neurocrine Biosciences, the American biotech, has unveiled new data showing its drug Crenessity (crinecerfont) may help ...

Irish contract research organization ICON (Nasdaq: ICON) has retained its position as the most active CRO worldwide in the ...

New York-based Pathos AI, a biotech company applying artificial intelligence (AI) to drug development, has announced a $365 ...

US clinical-stage biotech Therini Bio yesterday revealed that it raised $39 million in a Series A extension financing, which ...

The US Food and Drug Administration’s (FDA biosimilar approvals reached a record 19 in 2024, with projections indicating that ...

A federal jury in Delaware put US biotech major Amgen (Nasdaq: AMGN) on the hook Thursday for at least $271.2 million in ...

California’s BioMarin Pharmaceutical is to acquire Inozyme Pharma for $4 per share in an all-cash transaction for a total consideration of approximately $270 million.